Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial
نویسندگان
چکیده
منابع مشابه
Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial.
A multicentre trial of percutaneous calcitriol injection therapy (PCIT) was designed to evaluate its clinical usefulness. During a 12-week period, measurement of intact PTH concentration, and other parameters, and ultrasonography were carried out in conjunction with PCIT in 19 haemodialysis patients with secondary hyperparathyroidism and enlarged parathyroid glands (PTGs) that were resistant to...
متن کاملPercutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism.
BACKGROUND Secondary hyperparathyroidism (2HPT) is a frequent complication of long-term dialysis treatment and, despite recent advances in medical therapy, surgical parathyroidectomy (PTX) is required in a considerable number of uraemic patients. Recently, other modalities of therapy, such as ultrasound-guided percutaneous parathyroid injection of ethanol (PEIT) or of calcitriol (PCIT), have be...
متن کاملUse of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was 1.5 ± 1.7 cm(3), and 2.8 ± 2.8 cm(3) of ethanol was injected per patient. After ethanol injection...
متن کاملPercutaneous Ethanol Injection Therapy for Secondary Hyperparathyroidism in an Elderly Tracheostomized Hemodialysis Patient
Hyperparathyroidism, either secondary or tertiary, is a major complication of end stage renal disease (ESRD). It can result in renal bone disease if left untreated. Although surgical parathyroidectomy remains the treatment of choice, the appropriate therapy to treat hyperparathyroidism in specific patient groups such as tracheostomized patients has not been elucidated. We present a case of seco...
متن کاملA randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
BACKGROUND AND OBJECTIVES Calcitriol is used to treat secondary hyperparathyroidism in patients with CKD. Paricalcitol is less calcemic and phosphatemic in preclinical studies and in some trials in dialysis patients, but head-to-head comparisons in nondialysis patients are lacking. A large meta-analysis of trials concluded that these agents did not consistently reduce parathyroid hormone (PTH) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2003
ISSN: 1460-2385
DOI: 10.1093/ndt/gfg1010